About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

COMPLETEDNCT01933035

Extended Platelet Parameters as a Means to Differentiate Immune Thrombocytopenia From Hypo-proliferative Thrombocytopenias.

To utilise extended platelet parameters in order to individuate Immune Thrombocytopenia (ITP) from hypo-proliferative causes of thrombocytopenia. To develop the clinical potential of the extended pla...

Lead sponsor: Beth Israel Medical Center•1 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Beth Israel Medical Center

Patient to be registered at the Haematology-Oncology department Mount Sinai Roosevelt Hospital. Inclusion criteria are as follows: All individuals age 18yrs and above capable of rendering consent Known ITP confirmed by response to IVIG, glucocorticoids, or WinRho and exclusion of all other possible causes of thrombocytopenia Confirmed aplastic anemia \[as assessed through bone marrow trephine biopsy\]. Chemotherapy-induced thrombocytopenia assessed at time of predicted nadir.

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•All individuals age 18yrs and above capable of rendering consent
•Known ITP confirmed by response to intravenous immune globulin (IVIG), glucocorticoids, or winRho and exclusion of all other possible causes of thrombocytopenia
•Confirmed aplastic anemia \[as assessed through bone marrow trephine biopsy\]
•Chemotherapy induced thrombocytopenia assessed at time of predicted nadir.

Exclusion Criteria

•Suspected multifactorial thrombocytopenias and thrombocytopenia due to hypersplenism
•Chronic active hepatitis
•Those infected with HIV
•Patients receiving concomitant radiotherapy
•Gravid females
•Congenital thrombocytopenias

Related studies

RECRUITINGPhase 1/2

A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia

NCT06721013 · Immune Thrombocytopenia (ITP)

RECRUITINGPhase 2

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

NCT05564390 · Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, and more

RECRUITINGPhase 2

Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia

NCT05070845 · Primary Immune Thrombocytopenia

RECRUITINGPhase 2

Study of Ianalumab in Adults With Primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic Anemia (wAIHA) Who Have Previously Benefited From Ianalumab

NCT07039422 · Primary Immune Thrombocytopenia, Warm Autoimmune Hemolytic Anemia

RECRUITINGPhase 2

MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies

NCT05735717 · Hematologic Malignancy, Acute Leukemia, and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: May 17, 2016Terms

Trial snapshot

StatusCOMPLETED

Phase—

Enrollment50

Start dateOct 2013

Last updatedMay 17, 2016

Condition

Immune Thrombocytopenia Chemotherapy Induced Thrombocytopenia Myelodysplasia Aplastic Anaemia

Locations shown

Roosevelt Hospital

New York, New York

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 17, 2016Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions